Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.
Overview
- Center for Anatomy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department of Molecules – Signaling – Development, Max Planck Institute for Biological Intelligence, Martinsried, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Institute for Integrated Stress Response Signaling, Faculty of Medicine, University Hospital Cologne, Cologne, Germany
- Department of NMR Based Structural Biology, Max Planck Institute of Multidisciplinary Sciences, Göttingen, Germany
- Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- MODAG GmbH, Wendelsheim, Germany
- Cluster of Excellence “Multiscale Bioimaging: From Molecular Machines to Networks of Excitable Cells” (MBExC), University of Göttingen, Göttingen, Germany
- Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany
Abstract
Huntington’s disease (HD) is a hereditary movement disorder caused by a CAG repeat expansion in the huntingtin gene. HD is characterized by deposition of mutant huntingtin (mHTT) aggregates, and by severe neurodegeneration of the basal ganglia and neocortex. No cure is currently available, and new treatment options are urgently needed. Here, we show that the oligomer modifying molecule anle138b (INN: emrusolmin) improves multiple disease phenotypes in cell culture and in two mouse models of HD. Application of anle138b reduced mHTT aggregate formation and ameliorated neurotoxicity in primary neurons. Oral administration of anle138b delayed deposition of mHTT inclusions, reduced brain atrophy, mitigated neuroinflammation and transcriptional alterations, improved motor function and extended life span in HD mice. Downregulation of striatal markers and synapse loss in striatal spiny projection neurons were also partially rescued. No adverse effects of anle138b were observed in wildtype animals. Moreover, anle138b markedly decreased mHTT aggregation in human neural precursor cells differentiated from HD patient-derived induced pluripotent stem cells (iPSCs). Altogether these results illustrate the potential of anle138b as a disease-modifying treatment for HD.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- bioproject:PRJNA1429108, at NCBI BioProject; found in “Data availability”
Other data links
- ebi.ac.uk/
biostudies/ , EMBL-EBI; found in the text, “Author contributions”sourcedata
Data availability
The RNA-seq dataset generated in this study is available in the following database: Sequence read archive (SRA), PRJNA1429108 (https://
The source data of this paper are collected in the following database record: biostudies:S-SCDT-10_103
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 1 keyword, 11 MeSH terms, 1 funder, 76 references, 7 RRIDs.
Cite
This paper
da Silva Padilha, M., Koyuncu, S., Chabanis, E., Ryazanov, S., Leonov, A., Vilchez, D., Klein, R., Giese, A., Griesinger, C., & Dudanova, I. (2026). Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease. EMBO molecular medicine, 18(7), 2838-2866. https://
BibTeX
@article{dasilvapadilha2
author = {da Silva Padilha, Miguel and Koyuncu, Seda and Chabanis, Evangeline and Ryazanov, Sergey and Leonov, Andrei and Vilchez, David and Klein, Rüdiger and Giese, Armin and Griesinger, Christian and Dudanova, Irina},
title = {{Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease}},
journal = {EMBO molecular medicine},
year = {2026},
month = jun,
volume = {18},
number = {7},
pages = {2838--2866},
publisher = {Nature Publishing Group},
issn = {1757-4676},
doi = {10.1038/
url = {https://
pmid = {42362792},
pmcid = {PMC13365221}
}
RIS
TY - JOUR
AU - da Silva Padilha, Miguel
AU - Koyuncu, Seda
AU - Chabanis, Evangeline
AU - Ryazanov, Sergey
AU - Leonov, Andrei
AU - Vilchez, David
AU - Klein, Rüdiger
AU - Giese, Armin
AU - Griesinger, Christian
AU - Dudanova, Irina
TI - Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease
T2 - EMBO molecular medicine
J2 - EMBO Mol Med
PY - 2026
DA - 2026/
VL - 18
IS - 7
SP - 2838
EP - 2866
SN - 1757-4676
PB - Nature Publishing Group
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease",
"container-title": "EMBO molecular medicine",
"author": [
{
"family": "da Silva Padilha",
"given": "Miguel"
},
{
"family": "Koyuncu",
"given": "Seda"
},
{
"family": "Chabanis",
"given": "Evangeline"
},
{
"family": "Ryazanov",
"given": "Sergey"
},
{
"family": "Leonov",
"given": "Andrei"
},
{
"family": "Vilchez",
"given": "David"
},
{
"family": "Klein",
"given": "Rüdiger"
},
{
"family": "Giese",
"given": "Armin"
},
{
"family": "Griesinger",
"given": "Christian"
},
{
"family": "Dudanova",
"given": "Irina"
}
],
"container-title-short":
"volume": "18",
"issue": "7",
"page": "2838-2866",
"DOI": "10.1038/
"PMID": "42362792",
"PMCID": "PMC13365221",
"ISSN": "1757-4676",
"publisher": "Nature Publishing Group",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
26
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41467-025-64443-6
- Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation.Journal: Nature communicationsIn common: cellular / molecular, 8 references, author Christian Griesinger
- [2] doi:10.1038/s41586-026-10671-9 [code]
- Restoring cortical disinhibition improves Huntington's disease phenotypes.Journal: NatureIn common: other condition, mouse, 5 references, 2 authors
- [3] doi:10.1186/s40478-025-02054-4
- Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's disease.Journal: Acta neuropathologica communicationsIn common: other condition, mouse, cellular / molecular, 8 references
- [4] doi:10.1038/s41467-021-26684-z [code]
- Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, 7 references
- [5] doi:10.1038/s41591-023-02566-3
- Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.Journal: Nature medicineIn common: other condition, cellular / molecular, 7 references
- [6] doi:10.1186/s13195-023-01182-0 [code]
- Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b.Journal: Alzheimer's research & therapyIn common: mouse, cellular / molecular, 6 references
- [7] doi:10.1016/j.ymthe.2023.10.003 [code]
- Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington's disease mice and innervate the striatum.Journal: Molecular therapy : the journal of the American Society of Gene TherapyIn common: other condition, mouse, 7 references
- [8] doi:10.1038/s41593-024-01850-w
- Aberrant splicing in Huntington's disease accompanies disrupted TDP-43 activity and altered m6A RNA modification.Journal: Nature neuroscienceIn common: other condition, mouse, cellular / molecular, 8 references
- [9] doi:10.1016/j.mcpro.2023.100534
- Proteomic Analysis of Huntington's Disease Medium Spiny Neurons Identifies Alterations in Lipid Droplets.Journal: Molecular & cellular proteomics : MCPIn common: other condition, cellular / molecular, 6 references
- [10] doi:10.7554/elife.70217
- A novel and accurate full-length HTT mouse model for Huntington's disease.Journal: eLifeIn common: other condition, mouse, cellular / molecular, 6 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
